Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 16 Mar 2023
In Part 1 of the Obesity Series, Katherine H. Saunders, MD, DABOM discusses ways to treat childhood obesity, including the benefits of FDA-approved drugs and Intellihealth.
Read Full NewsNew York City’s revised Care Coordination Program may help reduce risks for all-cause and HIV-related deaths among people with HIV infection, including those at the highest risk for poor outcomes.
The drug was previously approved for stage 2 T1D.
Findings suggest young females should be assessed and, if at risk, monitored.
Final results from the PaTHway trial show the long-acting parathyroid hormone therapy enabled patients with hypoparathyroidism to achieve independence from high-dose calcium and vitamin D supplements.
Only 12% of patients prescribed testosterone underwent appropriate diagnostic testing, and overprescribing was common in a single-center US study.
The oral modulator of the calcium-sensing receptor targets the causes of ADH1, significantly improving serum and urine calcium levels.
Off-label alternatives for FDA-approved therapies can be as effective, cheaper, and in some cases safer despite never having been submitted for regulatory approval.
1.
Relationship-building key to addressing oncologist shortages in rural care
2.
Studies show that treatment for non-Hodgkin's lymphoma is also focused on the lymphoma.
3.
Could AI plus lasers help catch very early breast cancers?
4.
Promising OS at 5 Years With Chemo-Free Combo in Urothelial Cancer
5.
Children with the "Failure to Launch" Syndrome in Adulthood Have New Hope.
1.
The benefits and risks of taking fludrocortisone for adrenal insufficiency
2.
Understanding Melanoma: From Diagnosis to Healing and Excision in Denver
3.
Unlocking the Mystery of Ovarian Cancer Staging
4.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
5.
Unlocking the Potential of Cytarabine: A New Era of Cancer Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients
2.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
3.
Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients
4.
Thromboprophylaxis In Medical Settings
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge